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Abstract
Background: Non-pharmacological, non-surgical interventions are recommended as the first line of treatment
for osteoarthritis (OA) of the hip and knee. There is evidence that exercise therapy is effective for reducing pain
and improving function in patients with knee OA, some evidence that exercise therapy is effective for hip OA,
and early indications that manual therapy may be efficacious for hip and knee OA. There is little evidence as to
which approach is more effective, if benefits endure, or if providing these therapies is cost-effective for the
management of this disorder. The MOA Trial (Management of OsteoArthritis) aims to test the effectiveness of
two physiotherapy interventions for improving disability and pain in adults with hip or knee OA in New Zealand.
Specifically, our primary objectives are to investigate whether:
1. Exercise therapy versus no exercise therapy improves disability at 12 months;
2. Manual physiotherapy versus no manual therapy improves disability at 12 months;
3. Providing physiotherapy programmes in addition to usual care is more cost-effective than usual care alone in
the management of osteoarthritis at 24 months.
Methods: This is a 2 × 2 factorial randomised controlled trial. We plan to recruit 224 participants with hip or
knee OA. Eligible participants will be randomly allocated to receive either: (a) a supervised multi-modal exercise
therapy programme; (b) an individualised manual therapy programme; (c) both exercise therapy and manual
therapy; or, (d) no trial physiotherapy. All participants will continue to receive usual medical care. The outcome
assessors, orthopaedic surgeons, general medical practitioners, and statistician will be blind to group allocation
until the statistical analysis is completed. The trial is funded by Health Research Council of New Zealand Project
Grants (Project numbers 07/199, 07/200).
Discussion: The MOA Trial will be the first to investigate the effectiveness and cost-effectiveness of providing
physiotherapy programmes of this kind, for the management of pain and disability in adults with hip or knee OA.
Trial registration: Australian New Zealand Clinical Trials Registry ref: ACTRN12608000130369.
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Background
Non-pharmacological, non-surgical interventions, such as
the treatments offered by physiotherapists, are recom-
mended as the first line of treatment for hip and knee
osteoarthritis (OA) [1-3], however there is still insufficient
evidence about many such interventions to make specific
recommendations regarding management of this disorder
[4,5]. Given the prevalence of OA, its economic and
human burden, and accumulating evidence supporting
the effectiveness of various physiotherapy interventions
for patients with OA of the hip or knee, further research is
warranted [5]. Two common forms of physiotherapy
intervention are exercise therapy and manual therapy.
Although it is well established that various forms of exer-
cise are effective in reducing pain and increasing physical
function in people with knee OA, there is still little knowl-
edge about which forms of exercise are most effective [4-
8]. Little is known about whether effectiveness endures
beyond the medium term, with few studies following up
to 12 months, and none beyond 15 months [9]. Few trials
have investigated the relative benefits of differing exercise
approaches: systematic reviews of exercise therapy for the
osteoarthritic knee have included randomised controlled
trials, which are clinically diverse, with variability in the
interventions employed [4,7,9,10]. However, one meta-
analysis of trials on strengthening exercises concludes
that, to get the maximum benefit of strengthening exer-
cises, it is necessary to also include range-of-motion and
stretching exercises in a multi-modal approach [11]. There
are no trials that we know of investigating a supervised,
individualised, multi-modal programme of exercise ther-
apy for OA of the knee, although clinicians consider this
to characterise the 'ideal standard of clinical practice' [12].
Regarding OA of the hip, there have been very few ran-
domised controlled trials of exercise therapy, however
what data there are indicate the benefits may be similar to
those found for knee OA [5,11,13-15]. Although there are
no systematic reviews available specific to exercise thera-
pies for hip OA, reviews that have summarised either hip
and/or knee OA identified no trials of strengthening exer-
cises or of land-based supervised exercise for people with
OA of hip and had not undergone hip joint replacement
surgery [8,9,11,12,15]. Two more recent trials in the liter-
ature indicate that a programme of multimodal exercise
training and lifestyle advice [14] and a multi-modal
strengthening, stretching, gait training and range of
motion exercise programme [16] may be effective for
reducing pain and improving function in patients with
hip OA, however effect sizes were small in both trials.
Again, little is known about whether effectiveness endures
beyond the medium term.
New developments in manual physiotherapy have dem-
onstrated very promising improvements in pain and phys-
ical function [16-19], but effectiveness has not yet been
definitively established [5]. There is one clinical trial in
the literature of manual physiotherapy for hip OA: com-
pared with exercise physiotherapy, manual physiotherapy
resulted in superior improvements in pain and physical
function, that endured to six months follow-up [16].
Deyle and colleagues have conducted two trials of manual
physiotherapy for knee OA [17,18]. In the first, a multi-
modal intervention of individually tailored manual ther-
apy plus stretching, strengthening, range of motion and
home exercises resulted in clinically significant superior
outcomes compared with a placebo control group [18]. In
the second, the multi-modal intervention of individually
tailored manual therapy plus stretching, strengthening,
range of motion and home exercises resulted in clinically
significant superior outcomes compared with home exer-
cises alone [17]. In both studies, benefits were still evident
at the 12-month follow-up.
Our project is an extension of these recent studies [16-18],
and is designed to answer questions that have not been
addressed in the literature to date. None of the three pre-
vious controlled trials of manual physiotherapy has
directly compared manual therapy interventions with
usual care. We have identified no trials directly comparing
an individually tailored, supervised multi-modal exercise
therapy programme with usual care, or to individually tai-
lored manual therapy. No trials have investigated if there
is a synergistic, antagonistic or neutral effect when both
exercise and manual therapy are employed. Few of the
previous trials have assessed the effectiveness of their
interventions beyond a short to medium term. The MOA
Trial responds to the dearth of economic analysis studies
in this field, and will report cost-utility over a 24-month
timeframe.
The MOA Trial will investigate the long-term effectiveness
and cost-effectiveness of both a multi-modal, individual-
ised, supervised exercise therapy programme, and an indi-
vidualised manual therapy programme, for the
management of pain and disability in adults with hip or
knee OA. This publication outlines the design and analy-
sis plan for the MOA Trial.
Specific aims
The specific aims of this trial are to establish if:
1. Exercise therapy versus no exercise therapy improves
disability at 12 months in adults with hip or knee OA.
2. Manual therapy versus no manual therapy improves
disability at 12 months in adults with hip or knee OA.Trials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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3. Provision of physiotherapy programmes in addition to
usual care to adults with hip or knee OA is more cost-
effective than usual care alone at 24 months.
In addition, we will test for differences in the secondary
outcomes at 9 weeks, 6 months, and 12 months, and for
an interaction between the interventions for disability at
12 months. The secondary outcomes include physical per-
formance tests, patients' global assessment, and joint
replacement surgery (Table 1).
Trial design and methods
This project is a 2 × 2 factorial randomised controlled trial
(Figure 1). We have chosen a factorial design because it is
an efficient way to evaluate more than one intervention in
a single trial [20,21]. This is because all participants are
included in each of the primary analyses, whereas in a trial
of, say, three parallel arms evaluating two different inter-
ventions compared with a control arm, only two thirds of
participants are used for each comparison. However, the
sample size benefits gains of this design only occur when
the assumption of no interaction between the two inter-
ventions is met. We do not anticipate any interaction
effects since these are uncommon [21], even in drug trials
[20]. However, we will report an estimate of the interac-
tion effect as is recommended for all factorial trials [20]
(see Data Analysis, below).
Participants
We will recruit 224 participants through two sources: a)
patients attending general practitioners (GPs) with hip or
knee OA; and b) patients attending the Department of
Orthopaedic Surgery (Outpatient Clinic, Dunedin Hospi-
tal, New Zealand) for an orthopaedic consultation for
consideration of hip or knee joint replacement surgery.
To be eligible, participants must meet clinical criteria for
diagnosis of OA of the hip or knee according to American
College of Rheumatology criteria [22-24].
Exclusion criteria will include:
￿ previous knee or hip joint replacement surgery of the
affected joint;
￿ any other surgical procedure of the lower limbs in the
previous 6 months;
￿ rheumatoid arthritis;
￿ initiation of opioid analgesia or cortico-steroid or anal-
gesic injection intervention for hip or knee pain within
the previous 30 days;
￿ uncontrolled hypertension or moderate to high risk for
cardiac complications during exercise [25];
Table 1: Outcome measures
Primary Outcome measure* Data collection instrument
WOMAC composite score WOMAC-3.1 patient-rated questionnaire [30-32]
Secondary Outcome measures
Timed up-and-go Physical test [38,39]
30 second sit-to-stand Physical test [37]
40 m self-paced walk Physical test [32,39]
WOMAC subscales: A) Pain; B) Stiffness C) Physical Function; WOMAC-3.1 [33,34] patient-rated questionnaire
Numeric pain rating NPRS [33,34] patient-rated questionnaire
Self-efficacy and pain beliefs The Pain Belief Screening Instrument [40,41]
Depression The two-item case-finding instrument [42]
Patient's global assessment GROC [33,34,36] patient-rated scale
OARSI response criteria Composite of WOMAC, NPRS, GROC [34]
American College of Rheumatology criteria for diagnosis of OA Clinician-rated criteria [22-24,45,46] from physical tests and symptoms
New Zealand National Clinical Priority System score Clinician-rated criteria [47];
Adverse events MOA field team audit; ODHB records; self-report questionnaire
Overall health status† SF-12 general health survey [43]
Surgical intervention† Self-report questionnaire; health system records [44]
Healthcare consumption and related costs† Self-report questionnaire; health system records
*The primary end-point for data analysis is 12 months. All outcome measures will be undertaken at baseline, 9 weeks, 6 months, 1 year and 2 years, 
with the exception of patients' global assessment and OARSI response criteria, which will not be assessed at baseline. †The primary endpoint for 
cost-utility and surgical intervention is at 2 years. WOMAC = Western Ontario and McMaster osteoarthritis index; NPRS = numeric pain rating 
scale; GROC = global rating of change; OA = Osteoarthritis; OARSI = Osteoarthritis Research Society International; MOA = the Management of 
OsteoArthritis Trial; ODHB = Otago District Health Board.Trials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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￿ physical impairments unrelated to the hip or knee pre-
venting safe participation in exercise, manual therapy,
walking or stationary cycling, such as: vision problems
that affect mobility, body weight greater than 155 kg, neu-
rogenic disorder, primary or significantly limiting back
pain, advanced osteoporosis, or inability to walk 10
metres without an assistive device;
￿ inability to comprehend and complete study assess-
ments or comply with study instructions;
￿ stated inability to attend or complete the proposed
course of intervention and follow-up schedule.
Figure 2 shows a diagram illustrating the expected flow of
participants through recruitment, assessment and inter-
vention. A research nurse will identify potential partici-
pants at the Dunedin Hospital Orthopaedic Clinic point
of entry. The research nurse will initially screen each
potential participant against the inclusion and exclusion
criteria by chart review and questioning by telephone. We
will keep a screening log, recording the criteria eliminat-
ing all those found to be ineligible. Willing potential par-
ticipants will be given an appointment at the Centre for
Physiotherapy Research, where researchers will obtain
informed consent and baseline measures.
Researchers at the Centre for Physiotherapy Research will
evaluate each potential participant against the inclusion
and exclusion criteria by clinical history, physical exami-
nation and review of self-report questionnaires. Partici-
pants will then be randomised (refer to randomisation
and allocation concealment, below).
In the event of recruitment numbers falling behind tar-
gets, we will seek ethical approval to recruit people with
hip or knee OA by advertising in the community. Previous
research indicates there may be no clinically or statistically
significant differences in most important baseline meas-
ures or mean effects of treatment between patients
referred by GPs for clinical consultation versus people
recruited from the community via newspaper advertise-
ments [26].
Randomisation and allocation concealment
Participants will be randomised using TENALEA, which is
an online, central randomisation service, currently in
deployment phase with a grant from the e-TEN pro-
gramme of the European Union (LSHC-CT-510736). This
Trans-European Network for Clinical Trial Service pro-
vides a secure randomisation service over the internet. The
TENALEA service will generate and hold the randomisa-
tion schedule. Allocation concealment will be ensured, as
the service will not release the randomisation code until
the patient has been recruited into the trial, which takes
place after all baseline measurements have been com-
pleted.
Randomisation will be stratified by condition (hip or
knee). Within each stratum, participants will be ran-
domised to one of the four intervention groups using
block allocation. The block size will be subject to random
variation.
Blinding
Outcome assessors will be blind to group allocation, and
will not be involved in providing the interventions. The
2 × 2 factorial trial design Figure 1
2 × 2 factorial trial design. Note: All groups receive usual medical care.
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Diagram of participant flow Figure 2
Diagram of participant flow. OA = osteoarthritis; RN = Research Nurse; CRA = Clinical Research Administrator; MT = 
manual physiotherapy; Ex = exercise physiotherapy; GP = general medical practitioner.Trials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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orthopaedic surgeons and GPs managing the participants'
care will be blind to group allocation; physiotherapists
delivering the intervention cannot. The participants will
be informed they are in a "physiotherapy" or the "usual
care" group, and the type of physiotherapy intervention
(manual, exercise, or both) will not be specified. The stat-
isticians conducting the statistical analyses will be blind to
group allocation until the analyses are completed.
Interventions
Protocols for the physiotherapy interventions will be
described in a Manual of Standard Operating Procedures
(MSOP), available from the principal investigator (JHA).
Guidelines for individual tailoring of activity prescription
and progression will be described within these protocols.
Secondarily, additional interventions will be individually
tailored as needed, according to the results of a standard-
ised physical examination that will include tests and
measures to assess impairments in physical function (e.g.
muscle strength, muscle length, joint range of motion).
Impairments revealed will be matched explicitly to inter-
ventions, described in the MSOP, intended to directly
address each impaired physical function. In this manner,
the plan of care for each patient is individually tailored
from a standardised menu of interventions, using a
defined algorithm, in the categories of 'exercise therapy'
and 'manual therapy' (described below). Individualised
home exercise instructions, plus compliance logs, will
also be provided. The methodology will therefore be con-
sistent with the 'ideal standard of clinical practice' [12]
and the research designs of previous studies [16-18].
Participants randomised to receive trial physiotherapy
will receive nine treatment sessions: seven in the initial
nine weeks of the trial and two 'booster' sessions at week
16. Given the chronic, progressive nature of the disease,
we will recommend participants return to receive addi-
tional 'booster' doses of two sessions every four months,
as is recommended by current best evidence, previous
investigators and expert opinion [9,17,27,28].
Usual care
The control group will receive no trial physiotherapy. All
participants will continue to receive the usual, normal
routine care offered by their own GP and other healthcare
providers. In this way, this trial evaluates the effectiveness
of physiotherapy care in addition to usual medical care.
We will send a letter to each participant's GP informing
her or him that the patient is participating in the trial, but
will not reveal which group the patient is in and will
request that the GP not ask. We will also request that the
GP contact the researchers before adding physiotherapy to
the patient's plan of care during the trial. The researchers
will discourage contamination of the 'usual care only'
group by referral to physiotherapy within the 9-week
intervention phase, however it would be unethical and
unreasonable to recommend physiotherapy be withheld
from the 'usual care only' group throughout the follow-up
period of the trial. We will measure potential contamina-
tion with non-trial physiotherapy by participant self-
report questionnaire.
All participants will continue to receive their usual care at
the Dunedin Hospital Orthopaedic Clinic, by consultant
orthopaedic surgeons blind to group allocation. Participa-
tion in the trial will not affect patients' prioritisation for,
or access to, joint replacement surgery.
Exercise physiotherapy
The exercise therapy protocol will primarily consist of a
multi-modal, supervised programme of warm-up/aero-
bic, muscle strengthening, muscle stretching, and neu-
romuscular control exercises. Secondarily, additional
exercise therapy interventions will be prescribed individu-
ally for each participant on the basis of the physical exam-
ination findings, from a limited list of interventions
defined in the MSOP. These will be informed by evidence-
based best practice [5,9-13,16-18,29]. The protocol does
not allow therapist-applied manual forces. Participants
will be instructed in an individualised home exercise pro-
gramme of warm-up/aerobic, muscle strengthening, mus-
cle stretching, and neuromuscular control exercises as
detailed in the MSOP.
Manual physiotherapy
The manual therapy protocol will consist primarily of pro-
cedures intended to modify the quality and range of
motion of the target joint and associated soft tissue struc-
tures. Secondarily, additional manual therapy interven-
tions will be prescribed individually for each participant
randomised to this intervention on the basis of the phys-
ical examination findings, from a limited list of interven-
tions. These will be informed by evidence-based best
practice [16-19]. For our purposes, we define manual ther-
apy as the application of therapist-applied manual forces
in procedures intended to modify the quality and range of
motion of the target joint and soft tissue structures. The
protocol does not allow muscle strengthening or neu-
romuscular control exercises. Participants will be
instructed in an individualised home exercise programme
of joint range of motion exercises.
Combination therapy
This protocol will consist of a combination of both exer-
cise therapy and manual therapy interventions, as
described above.Trials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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Outcome measures
Primary
The primary outcome will be disability at one-year follow-
up using the WOMAC (Western Ontario and McMaster
osteoarthritis index). The WOMAC is a widely used, relia-
ble, valid and responsive measure of outcome in people
with osteoarthritis of the hip or knee [30-32].
Secondary
We will also include the outcome measures recom-
mended by OMERACT-OARSI guidelines [33,34]. These
require measures of pain, physical function and patient
global assessment. We will assess pain using the WOMAC
pain sub-scale and numeric pain rating scale [35]; physi-
cal function using the WOMAC physical function sub-
scale; and patient global assessment using a 15-point glo-
bal rating of change [36] (Table 1). We will also assess
change in physical performance tests: the timed up-and-
go, 30-second sit-to-stand, and 40 metre self-paced walk
tests [32,37-39] and psychological function [40-42]. We
will assess overall health status using the SF-12 (Quality
Metric, Inc., Lincoln, Rhode Island, USA) [43], and will
measure health care consumption costs, including surgi-
cal interventions, by records audit and patient self-report
questionnaire [44]. We will track and classify adverse
events. We will continue to assess the American College of
Rheumatology criteria for the diagnosis of OA of the hip
or knee [22-24,45,46]; the New Zealand National Clinical
Priority System score [47] (where available); and exercise
compliance.
Follow-up
A summary of the follow-up schedule is shown in Table 1.
Assessments will be performed by researchers at baseline,
9 weeks, 6 months, 1 year, 2 years and, if future funding
permits, subsequent years.
Sample size
The primary endpoint in this trial is disability at 12
months, measured using the numeric rating scale version
of the WOMAC scale. We calculated the sample size to
detect a difference of 28 points for each of the main
effects, namely, exercise therapy versus no exercise ther-
apy, and manual therapy versus no manual therapy. We
regard this as the minimum clinically important differ-
ence between groups in patients with moderate OA
[17,18,32,48-50]. Assuming a standard deviation of 50
points [17,18], and a type I error rate of 5%; a sample of
45 participants per intervention group (90 per row (Figure
1)) will be sufficient to detect the differences with approx-
imately 95% power. With a sample of this size, the pre-
dicted width of the 95% confidence interval for each
intervention effect will be approximately ± 14.6 points
[51]. Allowing for 20% attrition, we plan to recruit 56 par-
ticipants per group, providing a total of 224 participants.
Using the assumptions above, a sample of this size will
have limited power of approximately 46% to detect an
interaction between exercise therapy and manual physio-
therapy. However, these calculations may be conservative
since we have not incorporated the stratification variable,
or correlation between baseline and follow-up measures,
due to lack of prior information.
Data analysis
Analyses subsets
The primary analysis of the data will be undertaken using
the principle of intention-to-treat (ITT) [45]. Our ITT
analysis will include all participants, including those who
are not fully compliant and those with missing outcome
data. While we plan to implement procedures to mini-
mise loss to follow-up and patient withdrawal, we expect
to observe some attrition. We plan to employ multiple
imputation to handle missing data in the analysis. Multi-
ple imputation, compared to other case deletion strate-
gies, can provide valid inferences with less restrictive
assumptions surrounding the mechanism for missing
data [52-54].
As part of the secondary analyses, we plan to undertake
two per-protocol analyses for the primary outcome
(WOMAC composite score) at 12 months. The first analy-
sis will include participants who did not have hip or knee
replacement surgery. The second analysis will include par-
ticipants who complied with the intervention protocol;
where compliance will be defined as attendance of 80% of
scheduled intervention visits, 60% of prescribed home
exercise sessions in the intervention groups, and low con-
tamination (less than 4 physiotherapy visits) in the com-
parison group.
Descriptive analyses at baseline
Descriptive statistics will be presented by intervention
group at baseline to investigate the comparability between
groups. This will include summary statistics of demo-
graphic, stratification, baseline measures of outcomes,
and other potential confounding variables.
Primary analysis
Descriptive statistics for the WOMAC scale will be pre-
sented for each intervention group at 12 months follow-
up. We will evaluate the effectiveness of exercise therapy
and manual therapy on disability (WOMAC composite
score) at 12 months using analysis of covariance
(ANCOVA), a form of general linear model [55]. We will
include the baseline measure as a covariate in the model,
and include adjustment for the stratification variable
(condition), and pre-specified potential confounding fac-
tors: age, body mass index, baseline pain intensity, dura-
tion since first diagnosis, quadriceps muscle strength,
mental health, and self-efficacy [56]. These will beTrials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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included regardless of whether baseline imbalance exists.
This approach has been chosen because confounder selec-
tion strategies that are based on collected data can result
in models with poor statistical properties [57-59]. This
will adjust appropriately for any baseline imbalance and
will provide the most powerful analysis [57,60]. Adjusted
estimates of intervention effect from this model will be
reported as the primary analysis in the trial publication.
Secondary analyses
Secondary analyses will be undertaken using general lin-
ear models to investigate the effectiveness of the interven-
tions for the primary and secondary outcome variables at
9 weeks, 6 months, 12 months and 24 months. We will
include the same pre-specified confounding factors as in
the primary analysis, the stratification variable, and for
continuous outcomes collected at both baseline and fol-
low-up, we will include the baseline measure of the out-
come. In addition, estimates of the effectiveness of
exercise therapy and manual therapy from models that
only include the stratification variable and baseline meas-
ure of the outcome will also be presented.
We will report the event rates for joint replacement sur-
gery and the OMERACT-OARSI responder criteria [33,34],
and the number needed to treat (NNT) statistics. Logistic
regression methods and Cox's proportional hazards
model will be used to compare the risk of joint replace-
ment for each of the interventions at 12 month and 24
month follow-up. These models will include adjustment
for the stratification variable.
The effect of the interventions over time will be compared
using linear mixed models. These models appropriately
adjust for correlation that occurs from collecting multiple
observations per participant.
Finally, we will investigate (i) if there is an interaction
between the two interventions for the primary outcome at
12 months, and (ii) if the effects of the two interventions
differ by the condition (hip or knee osteoarthritis). For
these analyses we will include appropriate interaction
terms in the models [20,21]. The trial is not powered to
detect these interactions and is likely to have poor preci-
sion for the interaction terms. We plan to report regres-
sion coefficients for the interaction terms and their 95%
confidence intervals.
No statistical adjustment will be made for multiple test-
ing. All tests will be two-sided and carried out at the 5%
level of significance. Changes to the study design or anal-
ysis plan will be documented with full justification.
Economic evaluation
We will assess the incremental costs and the economic
consequences of delivering the manual therapy and exer-
cise programmes compared with usual care alone accord-
ing to established methods for the analysis of patient-level
data [61]. We will estimate all health care consumption
and costs from a societal perspective using patient self-
report questionnaires, and verify hospital admissions
from hospital records [62]. We will report incremental
cost-utility ratios using quality-adjusted life-years derived
from SF-12 scores using appropriate preference weight-
ings [63,64].
Trial organisation
Trial co-ordination and trial progress
The MOA Trial Team membership is listed in Table 2. The
principal investigator will co-ordinate the trial with the
assistance of a Clinical Research Administrator (CRA) and
chair regular meetings of the field team and co-investiga-
tor group. The co-investigators will monitor and support
the progress of the trial. The principal investigator and the
field team (i.e. physiotherapists, outcome assessors,
research nurse and CRA) will design the case reporting
forms and MSOPs, with advice from the clinical advisors
(Table 2), based on the best evidence available [5,9-14,16-
19,29]. The principal investigator and CRA will manage
the data flow, recording and storage.
The principal investigator will instigate and co-ordinate
the training of the field team and perform audits of proce-
dures throughout. Off-protocol and adverse event reports
will be monitored monthly. Each adverse event will be
independently adjudicated by two members of the MOA
Trial team, blind to participant group assignment, with a
third member to adjudicate in the event of disagreement.
Events will be reported to the Data and Safety Monitoring
Board.
Data and safety monitoring
Data and safety monitoring will initially be referred to the
Data and Safety Monitoring Board of the Health Research
Council of New Zealand. Should the Board consider the
risks low and/or the recruitment period short, they may
refer responsibility back to the MOA Trial Team. In this
event, we will set up a panel comprising the co-investiga-
tors, selected international advisors, and an independent
member to which the principal investigator will report
regularly.
In the event that more than one serious adverse event of
any type or class occurs that was avoidable and related to
the physiotherapy programmes, we will suspend the trial.
If the cause of the events cannot be determined, recon-
ciled or remediated, we will terminate the relevant arms of
the trial.Trials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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Data quality assurance
To enhance the accuracy of the data we will use optical
mark recognition technology (Remark™, Gravic, Inc., Mal-
vern, PA, USA) to transcribe data from paper forms to a
spreadsheet, which will input data directly into a rela-
tional database (FileMaker Pro™, FileMaker, Inc., Santa
Clara, CA, USA) based on a server in the Division of
Health Sciences, University of Otago. These methods ena-
ble transcription error to be minimised and eliminate the
need for manual double entry.
Intervention fidelity
Clinician adherence to the intervention protocols will be
ensured by collaborative development of the protocols
during a 3-day planning and training retreat, protocol-
based delivery, a comprehensive MSOP, field training,
structured recording forms, monthly field team meetings,
audit, observation, feedback, and participant interviews.
Publication policy
We will submit the results of the trial for publication in an
appropriate journal irrespective of outcome. We will
report the trial in accordance with the CONSORT state-
ments [65-67]. The principal investigator will be responsi-
ble for timely generation of report manuscripts, and prior
to submission the co-investigators will review and
approve study results papers arising from the MOA Trial.
The principal investigator must approve manuscripts aris-
ing from sub-studies nested within the MOA Trial pro-
gramme. Authorship of manuscripts, presentations and
reports related to the MOA Trial programme will comply
with the ICMJE "Uniform Requirements for Manuscripts
Submitted to Biomedical Journals" [68]. Other significant
contributors to the conduct of the MOA Trial will be indi-
vidually named under the umbrella "the MOA Trial
Team" (Table 2).
Timetable for the MOA Trial
June 2007 – Grant awarded by the Health Research Coun-
cil of New Zealand
November 2007 – Ethical approval granted by the Lower
South Regional Ethics Committee of the New Zealand
Ministry of Health
10 March 2008 – Recruitment starts
March 2009 – Recruitment completed
March 2009 – First participant completes 1-year follow-up
Table 2: The MOA Trial team
Name Role on trial team Affiliation
Dr J. Haxby Abbott Principal investigator University of Otago
Professor G. David Baxter Co-investigator University of Otago
Professor A. John Campbell Co-investigator; consultant geriatrician University of Otago
Associate Professor M. Clare Robertson Co-investigator; statistical analyst, economic evaluation University of Otago
Associate Professor Jean-Claude Theis Co-investigator; consultant orthopaedic surgeon University of Otago
Associate Professor Peter Herbison Statistician University of Otago
Joanne E. McKenzie Statistician University of Otago; Monash University
Professor Jeffrey Basford Research advisor Mayo Clinic
Associate Professor G. Kelley Fitzgerald Research and clinical advisor; advisor to PhD candidate University of Pittsburgh
Associate Professor Timothy Flynn Research and clinical advisor; advisor to PhD candidate Regis University
Associate Professor Julie Fritz Research advisor; advisor to PhD candidate University of Utah
Dr Deidre Hurley-Osing Research advisor University College Dublin
Debra McNamara Research nurse University of Otago
Catherine Chapple PhD candidate; outcome assessor University of Otago
Dr Daniel Pinto PhD candidate, economic evaluation; outcome assessor University of Otago
Dr Alexis Wright PhD candidate; outcome assessor University of Otago
Martin Kidd Physiotherapist University of Otago
Chris Higgs Physiotherapist University of Otago
Jessica Smith Physiotherapist University of Otago
Steve Tumilty Physiotherapist University of Otago
Dr Ewan Kennedy Physiotherapist University of Otago
Dr Rhiannon Braund Advisor to PhD candidate University of Otago
Associate Professor Josh Cleland Advisor to PhD candidate Franklin Pierce College
Associate Professor Chad Cook Advisor to PhD candidate Duke University
Dr John Dockerty Advisor to PhD candidate University of Otago
Associate Professor Paul Hansen Health economist; advisor to PhD candidate University of Otago
Professor Helen Nicholson Advisor to PhD candidate University of Otago
Dr Julie Whitman Clinical advisor Regis UniversityTrials 2009, 10:11 http://www.trialsjournal.com/content/10/1/11
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March 2010 – Last participant completes 1-year follow-up
June 2010 – Analysis and publication of 1-year data – re:
specific aims 1 & 2. Preliminary report of specific aim 3
March 2011 – Last participant completes 2-year follow-up
June 2011 – Analysis and publication of 2-year data – re:
specific aim 3, longer-term report of specific aims 1 & 2.
Discussion
The MOA Trial will be among the first randomised trials
to investigate the effectiveness and cost-utility of manual
therapy interventions and/or individually tailored, super-
vised multi-modal exercise therapy programmes for
patients with hip or knee OA. It will respond to the lack of
randomised trials to assess long-term outcomes or to
include economic analyses. The results will help to estab-
lish the best approach to primary care of adults with mild
to severe OA of the hip or knee.
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